{'fraction_non_alphanumeric': 0.02254791431792559, 'fraction_numerical': 0.006764374295377677, 'mean_word_length': 5.166666666666667, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[The role of various forms of ribomunyl in recurrent respiratory tract infections].

Ribomunyl was administered in an open clinical trial for the treatment of chronic repetitive infectious diseases of the upper respiratory tract. Two groups of patients were treated with either Ribomunyl aerosol (n = 19) or with Ribomunyl aerosol and injections (n = 17); a third group of 17 patients, serving as a control group, did not receive treatment with either form of Ribomunyl. The treatment lasted two months and was followed by an observation period of another four months. The patients treated with Ribomunyl showed a distinct improvement compared to the untreated group. Ribomunyl was generally well tolerated. Plasma antibodies determined before, during and after the trial showed a clear-cut relationship between the increase in plasma antibody levels and improvement of clinical picture.